{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:15:07Z","timestamp":1768997707894,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Medical University of Bia\u0142ystok","doi-asserted-by":"crossref","award":["123-52921\u2009L"],"award-info":[{"award-number":["123-52921\u2009L"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005297","name":"Medical University of Bia\u0142ystok","doi-asserted-by":"crossref","award":["133-52831L"],"award-info":[{"award-number":["133-52831L"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005297","name":"Medical University of Bia\u0142ystok","doi-asserted-by":"crossref","award":["N\/ST\/ZB\/16\/008\/1152"],"award-info":[{"award-number":["N\/ST\/ZB\/16\/008\/1152"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.cancergen.2017.04.066","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T14:21:54Z","timestamp":1493389314000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia"],"prefix":"10.1016","volume":"216-217","author":[{"given":"Ewa M.","family":"Wasilewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Panasiuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Gniot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sawicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Koz\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"K\u0142oczko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina T.","family":"Midro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2017.04.066_bib0010","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0015","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2010.02.005","article-title":"Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells","volume":"199","author":"Larsson","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0025","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4238\/2012.February.10.2","article-title":"Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia","volume":"11","author":"Hsiao","year":"2012","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cancergencyto.2010.08.017","article-title":"Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia","volume":"204","author":"Groves","year":"2011","journal-title":"Cancer Genet"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cancergen.2014.10.003","article-title":"Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment","volume":"207","author":"Gniot","year":"2014","journal-title":"Cancer Genet"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ccr3.506","article-title":"Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report","volume":"4","author":"Jawad","year":"2016","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0050","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.leu.2403210","article-title":"Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome","volume":"18","author":"Alimena","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.20226","article-title":"Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML)","volume":"77","author":"Patchenko","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0065","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","article-title":"Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"108","author":"Kovitz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0070","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ajh.20859","article-title":"Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome","volume":"82","author":"Navarro","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12185-008-0224-y","article-title":"Emergence of abnormal clone with monosomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors","volume":"89","author":"Conchon","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0080","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2169\/internalmedicine.50.4481","article-title":"Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia","volume":"50","author":"Karimata","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/10428194.2011.615425","article-title":"Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia","volume":"53","author":"Cannella","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergencyto.2006.04.012","article-title":"Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors","volume":"170","author":"Lin","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0095","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0100","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0105","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0110","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0120","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cncr.22699","article-title":"Characterization of Ph-negative abnormal clones emerging during imatinib therapy","volume":"109","author":"Abruzzese","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0125","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3324\/haematol.11064","article-title":"Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure","volume":"92","author":"Fabarius","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12032-012-0443-1","article-title":"Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia","volume":"30","author":"Bozkurt","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0135","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.11729","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"98","author":"Medina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cancergencyto.2006.12.011","article-title":"Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case","volume":"176","author":"Zeidan","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0145","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00277-013-1816-z","article-title":"Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy","volume":"92","author":"Wang","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-4608(02)00796-3","article-title":"Monosomy 21 in hematologic diseases","volume":"142","author":"Van Dyke","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10577-011-9198-3","article-title":"How to be a mitotic chromosome","volume":"19","author":"Moser","year":"2011","journal-title":"Chromosome Res"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0160","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.leu.2403861","article-title":"Induction of centrosome and chromosome aberrations by imatinib in vitro","volume":"19","author":"Fabarius","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0165","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0170","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cancergen.2017.04.066_bib0175","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.leu.2402791","article-title":"Clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib","volume":"17","author":"Meeus","year":"2003","journal-title":"Leukemia"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776216303453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776216303453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:43:16Z","timestamp":1761896596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776216303453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":34,"alternative-id":["S2210776216303453"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2017.04.066","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2017.04.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}